Enterprise Value
-98.44M
Cash
286.6M
Avg Qtr Burn
-21.87M
Short % of Float
16.84%
Insider Ownership
1.25%
Institutional Own.
97.41%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XMT-1660 (B7-H4 ADC) Details Ovarian cancer, Cancer, Breast cancer, Endometrial cancer | Phase 1 Data readout | |
XMT-2056 (HER2 ADC) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1 Update | |
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer | Failed Discontinued | |
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer | Failed Discontinued | |
Upifitamab Risodotin (UpRi) (XMT-1536) (NAPi2b ADC) Details Ovarian cancer, Solid tumor/s, Cancer | Failed Discontinued | |
XMT-1592 (NaPi2b antigen) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Failed Discontinued |